Neeta Pandit-Taskar, MD
Nuclear Medicine Physician
Molecular Imaging with PET/CT and PET/MR; Theranostics; Radiolabeled Antibodies, Small Molecules and Peptides, Beta and Alpha Emitters for Imaging and Targeted Cancer Therapies; Pediatric Malignancies
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Pandit-Taskar accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- The Empire Indemnity Plan provides limited coverage for our services.
Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, and HMO plans as well as their Enhanced Care Prime Network, which supports Medicaid Managed Care and Child Health Plus and Medicare plans. Memorial Sloan Kettering is also in-network with the New York State Essential Emblem Health plan, which can be purchased on the insurance exchange. Emblem Health does not include us in any of its Medicare plans or in any of its Select Care network plans. You must bring a referral from your Emblem primary care doctor to your first appointment.
Formerly known as Health Plus Amerigroup, Empire Blue Cross Blue Shield Health Plus is an in-network provider with Memorial Sloan Kettering. You will need a one-time referral from your primary care doctor.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We're here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
New York State Medicaid covers physician and hospital services at Memorial Sloan Kettering. Patients are responsible for co-payments.
We also have contractual relationships involving Medicaid Managed Care plans. MSK is an in-network provider with Medicaid NY Emblem Health (formerly known as HIP) and Medicaid NY Empire Blue Cross Blue Shield HealthPlus (formerly known as Amerigroup). You will need a one-time referral from your primary care doctor.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar's Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford's Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, Lady Hardinge Medical College (India)
Mount Sinai Medical Center (New York)
Memorial Sloan Kettering Cancer Center
I am a clinician-scientist who is board certified in nuclear medicine and nuclear cardiology. I have more than two decades of broad experience in clinical nuclear medicine and related research. I joined MSK in 2000. I am also Clinical Director of the Center for Radioimmunotargeted Imaging and Theranostics of the Ludwig Center for Cancer immunotherapy. Before coming to MSK, I was head of the nuclear medicine department at a cancer center in India. At MSK, I collaborate closely with medical oncologists and surgeons to provide conventional and novel methods of diagnosing and treating patients with radiolabled agents in a variety of malignancies. I have a special interest in treating pediatric cancers.
I provide clinical care in all aspects of radiopharmaceutical imaging (PET/CT, PET/MR, SPECT/CT, nuclear cardiology) and radionuclide therapy, and also conduct research involving the development of novel methods for diagnosis and treating cancers using radiolabeled agents. Over the years my work, both clinical and research, has increasingly focused on therapeutic applications, including theranostics – which is the combination of therapies and diagnostics – and treatment response assessment, with large and small radiolabeled molecular targeting agents.
My research involves radioimmunotargted agents, small molecules and peptides, alpha emitters, and the use of novel PET tracers and techniques like PET/CT and PET/MR for early assessment of disease status and response. As the principal investigator of a National Institutes of Health (NIH) RO1 grant from the National Cancer Institute, I am investigating new imaging techniques to detect and monitor neuroblastoma in children with PET/MR. The goal is to reduce radiation exposure and provide a rapid single-day imaging assessment to monitor disease and therapy response. I am also co-leading studies in theranostics in pediatric malignancies such as neuroblastoma, brain tumors, and other tumors including desmoplastic small round cell tumors.
My focus is on developing novel theranostic strategies with radiopharmaceuticals. I am studying the use of radiolabeled monoclonal antibodies to detect and treat cancers. My early research focused on the optimization of biodistribution and understanding the kinetics of radioimmunotargeted agents in variety of cancers. These include: Radiolabeled antibodies 8H9 and 3F8 for pediatric cancers such as metastatic neuroblastoma and brain tumors, and radioimmunoPET imaging and radioimmunotherapy for renal cancer, prostate cancer, ovarian cancer, pancreatic cancer, lymphoma, and colon cancer.
More recently, I have extended this work to utilize and optimize smaller molecules, ligands, and peptides for diagnoses and treatment. I have also looked at the use of alpha-emitter-conjugated radiolabeled antibodies in the treatment of malignancies. I am studying methods to improve the delivery of radiation to the tumors using image assessment and dose estimations to provide personalized therapy. Using novel hybrid PET/MR imaging, I am studying novel tracers to better diagnose and monitor treatment effect, which can also help guide management and therapy planning in the future. This will allow for lower radiation exposures when imaging pediatric patients.
I routinely perform radiopharmaceutical therapy with 131I-MIBG for neuroendocrine tumors including neuroblastoma, pheochromocytoma, and paraganglioma; bexxar and zevalin therapy for lymphoma; and Radium-di-chloride (xofigo) or samarium radionuclides to treat metastatic bone disease pain. I also perform microsphere therapy for liver metastasis (SIRT) with 90 Y sirspheres/theraspheres.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2012-2018)
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials Investigated by Dr. Pandit-Taskar
- A Pilot Trial of PET Imaging with (89)Zr-DFO-Trastuzumab in Esophagogastric Cancer
Clinical Trials Co-Investigated by Dr. Pandit-Taskar
- A Phase I Study of Convection-Enhanced Delivery of 124I-8H9 for Patients with Non-Progressive Diffuse Pontine Gliomas Previously Treated with Radiation Therapy
- A Phase I Study of Lintuzumab-Ac225 in People with Persistent Multiple Myeloma
- A Phase II Study of 131I-Omburtamab plus Radiotherapy in People with Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
- A Phase II Study of Adaptive Nivolumab and Ipilimumab Immunotherapy in Patients with Melanoma
- A Phase II/III Study of 131I-Omburtamab Radioimmunotherapy in Children with Neuroblastoma that has Spread to the Brain or Spinal Cord or the Lining Around the Brain
- A Phase III Study of Iomab-B plus Stem Cell Transplantation versus Conventional Chemotherapy in Older Patients with Recurrent or Persistent Acute Myeloid Leukemia
- A Pilot Phase II Study of Targeted Radiotherapy with 131I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Pandit-Taskar’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.